BROADWOOD PARTNERS, L.P.

Major 10% shareholder BROADWOOD PARTNERS buys 570,184 shares ($2.0M) at $3.56 avg across 6 transactions

BROADWOOD PARTNERS, L.P., a 10% owner, executed 6 separate purchases totaling 570,184 shares for $2,032,251.44 between April 16–27, 2026, at a blended average price of $3.56. The current price of $3.84 is 54.7% below the 52-week high of $8.48, and the stock is down 44.3% over the past 90 days, though up 7.9% over the past 30 days. The company is unprofitable (full-year net income was negative $10,854,000.00 with latest-quarter revenue of $260,000.00) but showed annual revenue growth of +115.6%. Broadwood's cross-ticker track record shows a 0.00% win rate at the 90-day mark with average returns of -14.9%, and its prior 5 trades at IMDX remain outcome-unmeasurable. The scale of this capital commitment—$2.0M added to an already substantial 12.68M-share position—alongside accumulation across depressed price levels and a period of recent gains (30-day +7.9%) follows multiple purchases by the same filer within days, warranting close monitoring of whether this reflects changed conviction about company fundamentals or portfolio allocation.

Broadwood Partners (10% owner) purchased 182,861 shares across 3 dates for $652,875.63; stock now -53.0% from 52-week high

Broadwood Partners executed 3 separate purchases totaling 182,861 shares between April 16–20, 2026 at a blended average price of $3.57, adding 1.5% to its existing 11.93M share position. The timing is concerning: the stock is currently trading at $3.99, down 53.0% from its 52-week high of $8.48 and down 6.3% over the past 30 days. Across the insider's cross-ticker track record, prior buys show an average 90-day return of -18.2% with a 0.00% win rate, and at IMDX specifically, the two prior buys in February 2026 posted 30-day returns of -15.0% and -34.0%. The company itself faces fundamental headwinds: while annual revenue grew 115.6%, the most recent quarter generated only $260,000 in revenue against a $-10.9M net loss, and the company was unprofitable over its most recent full fiscal year. The purchase does not reverse the negative momentum or address the underlying profitability challenges.

Broadwood Partners bought 670,213 shares in 3 tranches for $12.3M (avg $18.30) as stock down 34.1% from 52-week high.

Broadwood Partners, a director of STAAR Surgical, executed three separate purchases totaling 670,213 shares for $12,266,545.29 between March 11–13, 2026, at an average price of $18.30—well below the 52-week high of $28.57 but only 0.2% below the current price of $18.84. The company's fundamentals are distressed: annual revenue declined 23.7% year-over-year, the most recent full fiscal year was unprofitable, and the stock has fallen 21.9% over the past 90 days. Broadwood's prior trades at STAA—five buys in early January 2026—all posted negative 30-day returns (ranging from -19.9% to -21.9%), and none of the insider's broader cross-ticker buy history (20 prior buys with a 25% win rate at 90 days) demonstrated successful timing. This fresh accumulation in a deteriorating business environment, combined with a poor track record of buy timing at this specific ticker, suggests material risk rather than a conviction-driven inflection signal.

IMDX: Broadwood Partners acquires 521,739 shares for $2,999,999.25; stock down 34.2% from 52-week high despite 25.2% revenue growth.

Broadwood Partners, a 10% owner, purchased 521,739 shares at $5.75 on 2026-02-10 for $2,999,999.25, expanding holdings to 11,931,839 shares (+4.6% increase). The acquisition occurs against a backdrop of significant recent price weakness: the stock is -34.2% from its 52-week high of $8.48 and has declined -22.8% over the past 30 days. Simultaneously, the company reported 25.2% annual revenue growth, yet remains unprofitable with a net loss of $10,854,000.00 in its most recent full fiscal year and minimal quarterly revenue of $260,000.00. The cross-ticker track record shows this insider's prior 20 open-market buys yielded an average 90-day return of +10.4% with a 100.00% win rate, though zero measurable same-ticker outcomes exist. The open-market purchase at a price 3.0% above the current market price of $5.58 occurs during a steep drawdown, creating a key interpretive tension: whether the large position increase reflects conviction in the underlying business fundamentals or is simply a function of the insider's portfolio allocation discipline at price levels significantly above recent market levels.

BROADWOOD PARTNERS (10% owner) buys 27,485 shares at $22.05; 5 buys in 3 days amid -26.0% drop from 52-week high.

BROADWOOD PARTNERS, a 10% owner of STAAR SURGICAL, executed 2 separate purchases totaling 27,485 shares for $606,137.70 on 2026-01-09, at an average price of $22.05 per share. This transaction is part of a concentrated buying pattern—the filer has made 5 purchases at this ticker over a 3-day window (2026-01-06 through 2026-01-09), adding 27,485 shares to holdings of 15.45M shares. The timing occurs against a backdrop of significant stock decline: the current price of $21.13 is -26.0% from the 52-week high of $28.57 and down -12.4% over the past 30 days. The company's fundamentals show quarterly revenue of $94.7M with net income of $8.9M, but full-year profitability was negative (full-year net income was negative), and annual revenue growth contracted -2.6% year-over-year. Across BROADWOOD's cross-ticker open-market trading history, the filer has recorded a 100.00% 90-day win rate on 20 prior buys with average 90-day returns of +10.1%, though measurable outcomes are not yet available for any of the 5 same-ticker trades at STAA.

Broadwood Partners accumulates 406,653 STAA shares across 4 days for $8.8M as stock declines 11.4% in 30 days.

Broadwood Partners, a 10% shareholder, executed 8 separate purchases totaling 406,653 shares (406.7K shares) over 4 days (January 6–8, 2026) at prices ranging from $21.01 to $22.38, spending $8,817,663.73. The blended average purchase price of $21.68 sits above the current price of $22.50 and reflects buying activity during a 30-day decline of -11.4%. At STAA specifically, the insider's 5 prior buys over the preceding week (November 19–21) have returned -5.0% to -10.2% at the 30-day mark, with measurable 90-day outcomes still pending. The company reported negative full-year net income despite quarterly revenue of $94,732,000.00 ($94.7M) and faces annual revenue contraction of -2.6%. The multi-transaction structure and large capital deployment ($8.8M) during a period of weakening stock price and negative fundamentals merit attention to understand the buyer's assessment of valuation and near-term prospects.

Broadwood Partners purchases 1,500,000 shares for $41.1M at STAA; 10% holder adds 11.1% to holdings over 3 days

Broadwood Partners, a 10% shareholder, executed three separate open-market purchases totaling 1,500,000 (1.50M shares) over November 19–21 at a blended average price of $27.37, increasing holdings from 13,519,491 to 15,019,491 shares (+11.1%). The transaction size ($41,060,317.10) represents a material capital commitment, executed across three tranches at progressively higher prices ($26.42, $27.14, and $27.86). Notably, this insider's prior five trades at STAA were all well-timed, with all 5 of 5 prior buys producing positive 90-day returns (ranging from +6.6% to +12.9%). The current stock price of $28.00 sits 3.8% below the 52-week high of $29.10 but 12.4% above the 30-day average, and the company reported revenue of $94,732,000 and net income of $8,884,000 in the latest quarter, though full-year net income was negative. The sequential price escalation during the purchase window and the consistent pattern of prior well-timed buys at this ticker merit investor attention.

10% owner BROADWOOD PARTNERS bought 187,227 shares for $2,866,428.46 across 4 days at avg $15.31 vs stock now -70.2% from 52-wk high

BROADWOOD PARTNERS, L.P., a 10% owner, executed 8 separate purchases totaling 187,227 shares for $2,866,428.46 ($2.9M) between April 8–10, 2025, at a blended average price of $15.31, increasing its holdings from 13.33M to 13.52M shares. The timing coincides with acute price weakness: STAAR's stock is currently -70.2% from its 52-week high of $52.25 and down -15.1% in the past 30 days and -32.3% in the past 90 days. The company's fundamentals reflect deterioration—revenue declined -2.6% year-over-year, and it reported negative full-year net income despite recent quarterly profitability of $10.0M on $88.6M revenue. BROADWOOD's previous 5 same-ticker trades at STAA are all recent buys (April 4–7, 2025) with outcomes not yet measurable, indicating sustained accumulation into a depressed market for the stock.

STAA: 10% owner Broadwood Partners bought 845,220 shares (5 transactions) for $13,627,504.30 in early April, expanding holdings to 13.33M shares (+6.8%)

Broadwood Partners executed 5 separate purchases totaling 845,220 shares for $13,627,504.30 across April 2–7, 2025, at an average price of $16.12, reflecting a coordinated accumulation into STAA at levels near the 52-week low of $15.35. The stock has declined -69.1% from its 52-week high of $52.25, and the company is operating in a weak fundamental environment with annual revenue declining -2.6% and full-year net income negative. This series of discretionary open-market purchases by a 10% holder during a sharp drawdown is noteworthy given that the stock continues to trade -12.0% lower over the 30-day window and -32.4% lower over 90 days, and the prior five STAA trades by Broadwood are too recent to measure outcomes. The scale of this accumulation (adding 6.8% to existing holdings) by a major shareholder during a period of fundamental deterioration and share-price weakness is material to consider.

Broadwood Partners bought 53,969 shares (54.0K) for $941,285.43 across 4 transactions, expanding 12.49M position

Broadwood Partners, a 10% owner of STAA, executed 4 separate purchases totaling 53,969 shares for $941,285.43 at an average price of $17.44, adding 0.4% to its holdings of 12,487,044 shares post-transaction. The purchases occurred on 2025-03-31 and 2025-04-02 at prices ($17.46 and $17.43) near current levels ($17.60), representing transactions within a modest range during a period when the stock trades 66.3% below its 52-week high of $52.25. The company's fundamentals show recent quarterly revenue of $88,590,000.00 and net income of $10,000,000.00, though full-year results were negative. Prior activity at this ticker shows 5 buy transactions since 2025-03-26, all too recent for 90-day performance measurement, while the insider's broader cross-ticker buy history spans 20 prior transactions, with no measurable timing outcomes yet at this specific ticker.